Ardsley Advisory Partners’s ADMA Biologics ADMA Stock Holding History

Ardsley Advisory Partners’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.02M	Buy	600,000 +175,000	+41%	+$1.6M	0.52%	61
2026 Q1	$3.83M	Buy	+425,000	New	+$6.71M	0.49%	62
2025 Q4	–	Sell	-425,000	Closed	-$6.23M	–	145
2025 Q3	$6.23M	Buy	425,000 +25,000	+6%	+$429K	0.77%	46
2025 Q2	$7.28M	Buy	400,000 +100,000	+33%	+$2.04M	0.96%	35
2025 Q1	$5.95M	Buy	+300,000	New	+$5.19M	1.14%	28
2020 Q4	–	Sell	-94,100	Closed	-$225K	–	132
2020 Q3	$225K	Sell	94,100 -3,000	-3%	-$8.23K	0.04%	121
2020 Q2	$285K	Buy	97,100 +22,500	+30%	+$64.6K	0.06%	108
2020 Q1	$215K	Hold	74,600	–	–	0.08%	81
2019 Q4	$298K	Sell	74,600 -31,900	-30%	-$139K	0.05%	118
2019 Q3	$474K	Buy	106,500 +3,892	+4%	+$16.3K	0.11%	94
2019 Q2	$397K	Buy	102,608 +41,308	+67%	+$182K	0.06%	103
2019 Q1	$233K	Buy	61,300 +11,300	+23%	+$39.9K	0.04%	112
2018 Q4	$120K	Sell	50,000 -50,000	-50%	-$248K	0.03%	95
2018 Q3	$621K	Buy	100,000 +20,000	+25%	+$115K	0.08%	90
2018 Q2	$361K	Buy	+80,000	New	+$399K	0.05%	127

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ardsley Advisory Partners's ADMA Position: Q2 2026 in Review

Ardsley Advisory Partners increased its ADMA Biologics (ADMA) stake by 41% in Q2 2026, buying an estimated $1.6M and bringing the position to 600,000 shares worth $5.02M. The position accounts for 0.52% of the portfolio, ranked #61.

Ardsley Advisory Partners first reported a position in ADMA in Q2 2018 and has held it in 15 quarters since. The position peaked at $7.28M in Q2 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Ardsley Advisory Partners held 600,000 shares of ADMA Biologics worth $5.02M as of Q2 2026.
Ardsley Advisory Partners bought 175,000 ADMA Biologics shares in Q2 2026, an estimated $1.6M.
ADMA Biologics made up 0.52% of Ardsley Advisory Partners's portfolio in Q2 2026, its #61 holding.
Ardsley Advisory Partners first reported a position in ADMA Biologics in Q2 2018 and has held it in 15 quarters since.
Ardsley Advisory Partners's ADMA Biologics position peaked at $7.28M in Q2 2025.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Ardsley Advisory Partners's 13F filing for Q2 2026, filed 13 Jul 2026.